Hisao Imai

List of Publications by Citations

131 papers	2,286 citations	26 h-index	42 g-index
149 ext. papers	2,661 ext. citations	3.6 avg, IF	4.22 L-index

#	Paper	IF	Citations
131	Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. *British Journal of Cancer*, **2008**, 98, 742-8	8.7	166
130	Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. *Molecular Cancer Therapeutics*, **2011**, 10, 336-46	6.1	123
129	l-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms. *Cancer Science*, **2008**, 99, 2380-6	6.9	105
128	Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer. *Supportive Care in Cancer*, **2015**, 23, 1699-708	3.9	91
127	Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer. *Anticancer Research*, **2010**, 30, 4819-28	2.3	91
126	Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study. *Clinical Cancer Research*, **2007**, 13, 6369-78	12.9	90
125	Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer. *International Journal of Cancer*, **2012**, 130, 1733-44	7.5	65
124	Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma. *Lung Cancer*, **2009**, 66, 120-6	5.9	59
123	CD98 expression is associated with poor prognosis in resected non-small-cell lung cancer with lymph node metastases. *Annals of Surgical Oncology*, **2009**, 16, 3473-81	3.1	56
122	Expression of L-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung. *Pathology Research and Practice*, **2008**, 204, 553-61	3.4	49
121	Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease. *Cancer Chemotherapy and Pharmacology*, **2015**, 75, 521-6	3.5	48
120	Correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in non-small cell lung cancer. *Cancer Science*, **2009**, 100, 753-8	6.9	46
119	L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer. *Histopathology*, **2009**, 54, 804-13	7.3	43
118	Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer. *Oncogene*, **2013**, 32, 4034-42	9.2	42
117	A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer. *Lung Cancer*, **2010**, 69, 99-104	5.9	41
116	Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non-small-cell lung cancer. *BMC Cancer*, **2017**, 17, 571	4.8	39
115	Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in early stage squamous cell carcinoma of the lung. *Cancer Science*, **2009**, 100, 248-54	6.9	38

114	L-type amino acid transporter 1 (LAT1) is frequently expressed in thymic carcinomas but is absent in thymomas. *Journal of Surgical Oncology*, **2009**, 99, 433-8	2.8	37
113	Clinical significance of post-progression survival in lung cancer. *Thoracic Cancer*, **2017**, 8, 379-386	3.2	35
112	Unfavorable impact of cancer cachexia on activity of daily living and need for inpatient care in elderly patients with advanced non-small-cell lung cancer in Japan: a prospective longitudinal observational study. *BMC Cancer*, **2017**, 17, 800	4.8	34
111	Evaluation of thoracic tumors with (18)F-FMT and (18)F-FDG PET-CT: a clinicopathological study. *International Journal of Cancer*, **2009**, 124, 1152-60	7.5	32
110	Multiplexed molecular profiling of lung cancer using pleural effusion. *Journal of Thoracic Oncology*, **2014**, 9, 1048-1052	8.9	31
109	Mutant allele frequency predicts the efficacy of EGFR-TKIs in lung adenocarcinoma harboring the L858R mutation. *Annals of Oncology*, **2014**, 25, 1948-1953	10.3	28
108	Epigenetic inactivation of the thyroid hormone receptor beta1 gene at 3p24.2 in lung cancer. *Annals of Surgical Oncology*, **2010**, 17, 2222-8	3.1	28
107	Clinicopathological features of patients with bronchial-associated lymphoid tissue lymphoma. *Internal Medicine*, **2009**, 48, 301-6	1.1	27
106	Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer. *Annals of Thoracic Medicine*, **2015**, 10, 61-6	2.2	26
105	Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer. *BMC Cancer*, **2015**, 15, 989	4.8	25
104	Clinicopathological and prognostic significance of interleukin-8 expression and its relationship to KRAS mutation in lung adenocarcinoma. *British Journal of Cancer*, **2014**, 110, 2047-53	8.7	25
103	Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in surgically resectable stage III non-small cell lung cancer. *Experimental and Therapeutic Medicine*, **2010**, 1, 799-808	2.1	25
102	Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter. *Cancer Science*, **2018**, 109, 2539-2548	6.9	24
101	Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy. *BMC Cancer*, **2014**, 14, 18	4.8	24
100	Clinicopathological and therapeutic significance of CXCL12 expression in lung cancer. *International Journal of Immunopathology and Pharmacology*, **2010**, 23, 153-64	3	24
99	Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in patients with ovarian tumors. *American Journal of Translational Research (discontinued)*, **2015**, 7, 1161-71	3	23
98	A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol. *BMC Cancer*, **2019**, 19, 528	4.8	22
97	Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer. *Neoplasma*, **2014**, 61, 233-40	3.3	22

96	Comparison of L-type amino acid transporter 1 expression and L-[3-18F]-fluoromethyl tyrosine uptake in outcome of non-small cell lung cancer. *Nuclear Medicine and Biology*, **2010**, 37, 911-6	2.1	22
95	CXCR4+FOXP3+CD25+ lymphocytes accumulate in CXCL12-expressing malignant pleural mesothelioma. *International Journal of Immunopathology and Pharmacology*, **2009**, 22, 43-51	3	22
94	Expression of amino acid transporter (LAT1 and 4F2hc) in pulmonary pleomorphic carcinoma. *Human Pathology*, **2019**, 84, 142-149	3.7	22
93	A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations. *Lung Cancer*, **2018**, 126, 41-47	5.9	21
92	Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer. *Cancer Chemotherapy and Pharmacology*, **2020**, 85, 761-771	3.5	19
91	Rituximab monotherapy as a first-line treatment for pulmonary mucosa-associated lymphoid tissue lymphoma. *International Journal of Hematology*, **2015**, 101, 46-51	2.3	18
90	Identification of actionable mutations in malignant pleural mesothelioma. *Lung Cancer*, **2014**, 86, 35-40	5.9	18
89	Surrogate endpoints for overall survival in advanced non-small-cell lung cancer patients with mutations of the epidermal growth factor receptor gene. *Molecular and Clinical Oncology*, **2014**, 2, 731-736	1.6	18
88	Management of malignant pericardial effusion with instillation of mitomycin C in non-small cell lung cancer. *Japanese Journal of Clinical Oncology*, **2005**, 35, 57-60	2.8	17
87	Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer. *Cancer Chemotherapy and Pharmacology*, **2017**, 79, 497-505	3.5	15
86	First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations. *Cancer Chemotherapy and Pharmacology*, **2015**, 76, 761-9	3.5	14
85	Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy. *Medical Oncology*, **2014**, 31, 88	3.7	13
84	Incidence of opioid-induced constipation in Japanese patients with cancer pain: A prospective observational cohort study. *Cancer Medicine*, **2019**, 8, 4883-4891	4.8	12
83	Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations. *Clinical and Translational Oncology*, **2015**, 17, 702-9	3.6	12
82	A phase I dose-escalation study of S-1 plus carboplatin in patients with advanced non-small-cell lung cancer. *Anti-Cancer Drugs*, **2007**, 18, 471-6	2.4	12
81	Clinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer. *Thoracic Cancer*, **2016**, 7, 655-662	3.2	11
80	Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide. *Canadian Respiratory Journal*, **2016**, 2016, 5405810	2.1	11
79	Decreasing expression of glucose-regulated protein GRP78/BiP as a significant prognostic predictor in patients with advanced laryngeal squamous cell carcinoma. *Head and Neck*, **2016**, 38, 1539-44	4.2	11

78	The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor. *International Journal of Clinical Oncology*, **2015**, 20, 668-73	4.2	10
77	Acidic pH increases cGMP accumulation through the OGR1/phospholipase C/Ca(2+)/neuronal NOS pathway in N1E-115 neuronal cells. *Cellular Signalling*, **2014**, 26, 2326-32	4.9	10
76	Phase 2 study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer. *Lung Cancer*, **2010**, 68, 253-7	5.9	10
75	Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥75 years) with non-small cell lung cancer. *Journal of Cancer Research and Clinical Oncology*, **2020**, 146, 457-466	4.9	10
74	Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer. *Cancer Chemotherapy and Pharmacology*, **2017**, 79, 165-171	3.5	9
73	Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status. *Japanese Journal of Clinical Oncology*, **2019**, 49, 671-675	2.8	9
72	Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study. *Oncologist*, **2018**, 23, 1210-1217	5.7	9
71	A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients. *Cancer Chemotherapy and Pharmacology*, **2017**, 80, 615-622	3.5	9
70	Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy. *Chemotherapy*, **2017**, 62, 205-213	3.2	8
69	Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial. *Oncologist*, **2019**, 24, 593-e170	5.7	8
68	Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment. *Thoracic Cancer*, **2020**, 11, 2188-2195	3.2	8
67	Efficacy and safety of platinum combination chemotherapy re-challenge for relapsed patients with non-small-cell lung cancer after postoperative adjuvant chemotherapy of cisplatin plus vinorelbine. *Chemotherapy*, **2013**, 59, 307-13	3.2	8
66	Reversible posterior leukoencephalopathy syndrome after carboplatin and paclitaxel regimen for lung cancer. *Internal Medicine*, **2012**, 51, 911-5	1.1	8
65	Clinical impact of postprogression survival for overall survival in elderly patients (aged 75 years or older) with advanced nonsmall cell lung cancer. *Journal of Cancer Research and Therapeutics*, **2015**, 11, 606-11	1.2	8
64	A phase I dose escalation study of weekly docetaxel and carboplatin in elderly patients with nonsmall cell lung cancer. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2007**, 30, 51-6	2.7	7
63	Prognostic significance of GRP78/BiP expression in patients with Stage III/IV hypopharyngeal squamous cell carcinoma. *Neoplasma*, **2016**, 63, 477-83	3.3	7
62	High expression of GRP78/BiP as a novel predictor of favorable outcomes in patients with advanced thymic carcinoma. *International Journal of Clinical Oncology*, **2017**, 22, 872-879	4.2	6
61	Successful afatinib treatment of advanced non-small-cell lung cancer patients undergoing hemodialysis. *Cancer Chemotherapy and Pharmacology*, **2017**, 79, 209-213	3.5	6

60	Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial. *Investigational New Drugs*, **2020**, 38, 1854-1861	4.3	6
59	Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy. *Radiology and Oncology*, **2015**, 49, 409-15	3.8	6
58	Pre-existing interstitial lung disease does not affect prognosis in non-small cell lung cancer patients with PD-L1 expression ≥50% on first-line pembrolizumab. *Thoracic Cancer*, **2021**, 12, 304-313	3.2	6
57	Comparison of the time-to-response between radiotherapy and epidermal growth factor receptor--tyrosine kinase inhibitors for advanced non-small cell lung cancer with EGFR mutation. *Anticancer Research*, **2013**, 33, 3279-84	2.3	6
56	Post-progression survival is highly linked to overall survival in patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors. *Thoracic Cancer*, **2019**, 10, 2200-2208	3.2	5
55	Primary malignant melanoma of the trachea: A case report. *Oncology Letters*, **2015**, 9, 657-660	2.6	5
54	Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy. *SpringerPlus*, **2015**, 4, 152		5
53	Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients. *Respiratory Investigation*, **2014**, 52, 101-6	3.4	5
52	Perianal metastasis of non-small cell lung cancer. *Internal Medicine*, **2014**, 53, 1149-52	1.1	5
51	Outcome of platinum-based chemotherapy for non-small-cell lung cancer patients with pleural dissemination detected during surgery. *Molecular and Clinical Oncology*, **2013**, 1, 949-952	1.6	5
50	Intrapericardial carboplatin in the management of malignant pericardial effusion in breast cancer: a pilot study. *Cancer Chemotherapy and Pharmacology*, **2019**, 84, 655-660	3.5	4
49	Prognostic effect of class III β-tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors. *Oncology Letters*, **2017**, 14, 2369-2378	2.6	4
48	A phase I dose escalation study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA nonsmall cell lung cancer. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2007**, 30, 498-502	2.7	4
47	Effectiveness of EGFR-TKI rechallenge immediately after PD-1 blockade failure. *Thoracic Cancer*, **2021**, 12, 864-873	3.2	4
46	An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer. *Anticancer Research*, **2019**, 39, 2483-2491	2.3	3
45	Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment. *Journal of Clinical Medicine*, **2020**, 9,	5.1	3
44	Prognostic Significance of Glucose Metabolism as GLUT1 in Patients with Pulmonary Pleomorphic Carcinoma. *Journal of Clinical Medicine*, **2020**, 9,	5.1	3
43	Administration of docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte colony-stimulating factor for pretreated non-small cell lung cancer: a phase II study. *Supportive Care in Cancer*, **2020**, 28, 4825-4831	3.9	3

42	Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer. *International Journal of Clinical Oncology*, **2016**, 21, 240-247	4.2	3
41	Clinical Impact of Post-Progression Survival on Overall Survival in Elderly Patients with Non-Small-Cell Lung Cancer Harboring Sensitive EGFR Mutations Treated with First-Line EGFR Tyrosine Kinase Inhibitors. *Chemotherapy*, **2018**, 63, 181-189	3.2	3
40	Clinical Significance of Various Drug-Sensitivity Markers in Patients with Surgically Resected Pulmonary Pleomorphic Carcinoma. *Cancers*, **2019**, 11,	6.6	3
39	Prognostic Significance of Tumor Immunity in Surgically Resected Pulmonary Pleomorphic Carcinoma. *Anticancer Research*, **2020**, 40, 261-269	2.3	3
38	PatientsR Self-Assessment of the Symptoms and Impact of Opioid-Induced Constipation: Results From a Prospective Observational Cohort Study of Japanese Patients With Cancer. *Journal of Pain and Symptom Management*, **2020**, 59, 1043-1051.e2	4.8	3
37	Prognostic factors for patients with metastatic or recurrent thymic carcinoma receiving palliative-intent chemotherapy. *Lung Cancer*, **2020**, 148, 122-128	5.9	3
36	Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis. *Thoracic Cancer*, **2018**, 9, 1699-1706	3.2	3
35	Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer. *Cancer Medicine*, **2021**, 10, 6971-6984	4.8	3
34	The effect of post-progression survival on overall survival among patients with sensitive relapse of small cell lung cancer. *Medical Oncology*, **2018**, 35, 45	3.7	2
33	Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations. *Cancer Chemotherapy and Pharmacology*, **2018**, 82, 119-127	3.5	2
32	Dramatic Response of S-1 Administration to Chemorefractory Advanced Thymic Cancer. *Chemotherapy*, **2014**, 60, 356-9	3.2	2
31	Prospective exploratory study of gemcitabine and S-1 against elderly patients with advanced non-small cell lung cancer. *Oncology Letters*, **2017**, 14, 1123-1128	2.6	2
30	Hydroxyurea-induced Pneumonitis in a Patient with Chronic Myelomonocytic Leukemia: An Autopsy Case. *Internal Medicine*, **2015**, 54, 3171-6	1.1	2
29	Clinical features of patients with invasive thymoma: A retrospective analysis of 61 cases. *Surgical Practice*, **2013**, 17, 140-148	0.4	2
28	Recurrence of mantle cell lymphoma occurring in the tracheobronchial wall. *Internal Medicine*, **2012** , 51, 1143-4	1.1	2
27	Metachronous bilateral breast metastases of a lung neuroendocrine tumor: A case report. *Molecular and Clinical Oncology*, **2020**, 13, 53	1.6	2
26	Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel as Second- or Third-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer. *Chemotherapy*, **2020**, 65, 21-28	3.2	2
25	Efficacy and safety of S-1 monotherapy in previously treated elderly patients (aged ≥75 years) with non-small cell lung cancer: A retrospective analysis. *Thoracic Cancer*, **2020**, 11, 2867-2876	3.2	2

24	Low-Dose Olanzapine Plus Granisetron and Dexamethasone for Carboplatin-Induced Nausea and Vomiting in Patients with Thoracic Malignancies: A Prospective Multicenter Phase II Trial. *Oncologist*, **2021**, 26, e1066-e1072	5.7	2
23	Opioid-induced constipation in patients with cancer pain in Japan (OIC-J study): a post hoc subgroup analysis of patients with gastrointestinal cancer. *International Journal of Clinical Oncology*, **2021**, 26, 104-110	4.2	2
22	Post-Progression Survival Influences Overall Survival among Patients with Advanced Non-Small Cell Lung Cancer Undergoing First-Line Pembrolizumab Monotherapy. *Oncology*, **2021**, 99, 562-570	3.6	2
21	Re: INSM1 is a novel prognostic neuroendocrine marker for luminal B breast cancer. *Pathology*, **2021**, 53, 292-293	1.6	2
20	Tumor immunity is related to F-FDG uptake in thymic epithelial tumor. *Cancer Medicine*, **2021**, 10, 6317-6326	4.8	2
19	Recurrent intimal sarcoma mimicking pulmonary embolism. *Japanese Journal of Clinical Oncology*, **2015**, 45, 695-6	2.8	1
18	Differences in the efficacy of S-1 monotherapy according to histological type in pretreated patients with advanced non-small cell lung cancer. *Thoracic Cancer*, **2014**, 5, 121-5	3.2	1
17	Papillary squamous cell carcinoma of the trachea associated with human papillomavirus-18 infection. *Internal Medicine*, **2013**, 52, 2785-8	1.1	1
16	Association Between Laryngopharyngeal Reflux and Radiation-induced Mucositis in Head and Neck Cancer. *Anticancer Research*, **2018**, 38, 477-480	2.3	1
15	Prognostic value of morphological characteristics assessed by CT scan in patients with non-small cell lung cancer treated with nivolumab. *Thoracic Cancer*, **2020**, 11, 3521-3527	3.2	1
14	Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers. *Frontiers in Oncology*, **2021**, 11, 610952	5.3	1
13	Post-Progression Survival Is Strongly Associated with Overall Survival in Patients Exhibiting Postoperative Relapse of Non-Small-Cell Lung Cancer Harboring Sensitizing Mutations. *Medicina (Lithuania)*, **2021**, 57,	3.1	1
12	Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials. *BMC Cancer*, **2021**, 21, 832	4.8	1
11	Factors affecting the performance of activities of daily living in patients with advanced cancer undergoing inpatient rehabilitation: results from a retrospective observational study. *Journal of Physical Therapy Science*, **2019**, 31, 795-801	1	1
10	Opioid-induced constipation in patients with cancer pain in Japan (OIC-J study): a post hoc subgroup analysis of patients with lung cancer. *Japanese Journal of Clinical Oncology*, **2021**, 51, 444-450	2.8	1
9	Clinical impact of post-progression survival on overall survival in patients receiving nivolumab monotherapy as a second-line treatment for advanced non-small cell lung cancer. *Thoracic Cancer*, **2021**, 12, 1171-1179	3.2	1
8	Course of postoperative relapse in non-small cell lung cancer is strongly associated with post-progression survival. *Thoracic Cancer*, **2021**, 12, 2740-2748	3.2	1
7	Efficacy and Safety of Anti-Programed Death-1 Blockade in Previously Treated Large-Cell Neuroendocrine Carcinoma. *Chemotherapy*, **2021**, 66, 65-71	3.2	1

6	Management of Lung Cancer-Associated Malignant Pericardial Effusion with Intrapericardial Administration of Carboplatin: A Retrospective Study.. *Current Oncology*, **2021**, 29, 163-172	2.8	1
5	Post-progression survival is strongly linked to overall survival in refractory small-cell lung cancer patients who received amrubicin. *Journal of Cancer Research and Therapeutics*, **2020**, 16, 764-770	1.2	0
4	A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer -TCOG 1101. *International Journal of Clinical Oncology*, **2020**, 25, 867-875	4.2	
3	Prognostic Significance of Diabetes Mellitus in Locally Advanced Non-small Cell Lung Cancer. *Kitakanto Medical Journal*, **2017**, 67, 87-88	0	
2	Prospective Feasibility Study of Amrubicin and Bevacizumab Therapy for Patients With Previously Treated Advanced NSCLC. *Anticancer Research*, **2020**, 40, 1571-1578	2.3	
1	Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis.. *BMC Cancer*, **2022**, 22, 310	4.8	